It was recently reported that treatment of AR-expressing bladder cancer cell lines with enzalutamide induced up-regulation of tumor suppressor, p53, p21 and PTEN, and down-regulation of several oncogenic genes, such as c-myc, cyclin D1, and cyclin E [38]. The gene discussed is CCNE1; the disease is urinary bladder carcinoma.